Literature DB >> 20002653

C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy.

S Coimbra1, H Oliveira, F Reis, L Belo, S Rocha, A Quintanilha, A Figueiredo, F Teixeira, E Castro, P Rocha-Pereira, A Santos-Silva.   

Abstract

BACKGROUND: Psoriasis vulgaris is a chronic recurrent inflammatory skin disease and psoriatic lesions have shown leucocyte infiltration.
OBJECTIVES: We aimed to study C-reactive protein (CRP) and leucocyte activation markers/inhibitors as potential monitors of psoriasis vulgaris.
METHODS: A cross-sectional (n = 73) and a longitudinal study (before, at 3, 6 and 12 weeks of therapy; n = 47) was performed; 10 patients started topical treatment, 17 narrow-band ultraviolet light B (NBUVB) and 20 psolaren associated to UVA (PUVA); psoriasis severity was defined by Psoriasis Area and Severity Index (PASI).
RESULTS: Compared with control (n = 38), we found higher CRP levels, total leukocyte/neutrophil count, elastase, lactoferrin and alpha1-antitrypsin. Increasing PASI was linked to increasing CRP and a trend to higher elastase and lactoferrin, suggesting that worsening enhances inflammatory response with neutrophil activation. CRP correlated with PASI, total leucocytes, neutrophils, elastase, lactoferrin and alpha1-antitrypsin. NBUVB and PUVA presented similar effects.
CONCLUSION: We propose CRP as a useful marker of psoriasis severity that could be used to monitor psoriasis and its treatment, and, together with PASI and elastase, could also be used as a global index of severity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002653     DOI: 10.1111/j.1468-3083.2009.03527.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  28 in total

1.  Evaluation of systemic oxidant/antioxidant status and paraoxonase 1 enzyme activities in psoriatic patients treated by narrow band ultraviolet B phototherapy.

Authors:  S D Pektas; G Akoglu; A Metin; S Neselioglu; O Erel
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

2.  Lack of association between the genetic variations in the C-reactive protein gene and the risk of psoriasis among the Taiwanese.

Authors:  Ya-Ching Chang; Wei-Ming Wu; Lung-An Hsu
Journal:  Mol Biol Rep       Date:  2011-07-20       Impact factor: 2.316

3.  TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.

Authors:  Julie J Hong; Edward K Hadeler; Megan L Mosca; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2022-01-12

4.  Assessment of left atrial volume and function in patients with psoriasis by using real time three-dimensional echocardiography.

Authors:  Halil Atas; Alper Kepez; Mehmet Bozbay; Dilek Seckin Gencosmanoglu; Altug Cincin; Murat Sunbul; Ayfer Yildiz Bozbay; Ramila Darvishova; Tulin Ergun
Journal:  Wien Klin Wochenschr       Date:  2015-07-31       Impact factor: 1.704

5.  Relationship Between the Serum Total Bilirubin and Inflammation in Patients With Psoriasis Vulgaris.

Authors:  Zhen-Xing Zhou; Jian-Kui Chen; Yan-Ying Hong; Ru Zhou; Dong-Mei Zhou; Li-Yun Sun; Wen-Li Qin; Tian-Cheng Wang
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

6.  Factors associated with the length of remission of psoriasis vulgaris.

Authors:  Susana Coimbra; Hugo Oliveira; Américo Figueiredo; Petronila Rocha-Pereira; Alice Santos-Silva
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

Review 7.  Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 8.  Pathogenic mechanisms shared between psoriasis and cardiovascular disease.

Authors:  Ramin Ghazizadeh; Hajime Shimizu; Mamiko Tosa; Mohammad Ghazizadeh
Journal:  Int J Med Sci       Date:  2010-08-19       Impact factor: 3.738

9.  Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.

Authors:  Jochen H O Hoffmann; Christian Knoop; Knut Schäkel; Alexander H Enk; Eva N Hadaschik
Journal:  Acta Derm Venereol       Date:  2021-05-25       Impact factor: 3.875

10.  Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis.

Authors:  Asha Ramay Vadakayil; Sukumar Dandekeri; Srinath M Kambil; Neema M Ali
Journal:  Indian Dermatol Online J       Date:  2015 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.